

# Cisplatin-Induced DNA Damage Activates Replication Checkpoint Signaling Components that Differentially Affect Tumor Cell Survival<sup>[S]</sup>

Jill M. Wagner and Larry M. Karnitz

*Departments of Molecular Pharmacology & Experimental Therapeutics (J.M.W., L.M.K.) and Radiation Oncology (L.M.K.) and Division of Oncology Research (J.M.W., L.M.K.), Mayo Clinic, College of Medicine, Rochester, Minnesota*

Received January 29, 2009; accepted April 28, 2009

## ABSTRACT

Cisplatin and other platinating agents are some of the most widely used chemotherapy agents. These drugs exert their antiproliferative effects by creating intrastrand and interstrand DNA cross-links, which block DNA replication. The cross-links mobilize signaling and repair pathways, including the Rad9-Hus1-Rad1-ATR-Chk1 pathway, a pathway that helps tumor cells survive the DNA damage inflicted by many chemotherapy agents. Here we show that Rad9 and ATR play critical roles in helping tumor cells survive cisplatin treatment. However, depleting Chk1 with small interfering RNA or inhibiting Chk1 with

3-(carbamoylamino)-5-(3-fluorophenyl)-N-(3-piperidyl)thiophene-2-carboxamide (AZD7762) did not sensitize these cells to cisplatin, oxaliplatin, or carboplatin. Moreover, when Rad18, Rad51, BRCA1, BRCA2, or FancD2 was disabled, Chk1 depletion did not further sensitize the cells to cisplatin. In fact, Chk1 depletion reversed the sensitivity seen when Rad18 was disabled. Collectively, these studies suggest that the pharmacological manipulation of Chk1 may not be an effective strategy to sensitize tumors to platinating agents.

The platinum-based chemotherapy drugs cisplatin, carboplatin, and oxaliplatin are among the most active and widely used agents for the treatment of malignancies, including testicular, head and neck, ovarian, lung, colorectal, and bladder cancers (Kelland, 2007). It is generally accepted that these agents kill tumor cells primarily by creating DNA lesions, which are most cytotoxic during S-phase, probably because the lesions are potent inhibitors of DNA replication (Donaldson et al., 1994).

When a replication fork is stalled by either intra- or interstrand cross-links, sophisticated repair and signaling pathways are called into action. In the case of bulky adducts such as intrastrand cross-links (which comprise the majority of platin-induced lesions), the stalled replication fork triggers the monoubiquitylation of proliferating cell nuclear antigen (Lehmann, 2006). Ubiquitylated proliferating cell nuclear antigen then recruits one or more translesion synthesis (TLS) polymerases, which have active sites that can accom-

modate bulky lesions, thereby allowing error-prone bypass of the lesion. In contrast, interstrand cross-links, which account for a few percentage of cisplatin-induced DNA lesions but are far more cytotoxic, cannot be simply bypassed. Instead, their repair involves a complex interplay between a series of DNA repair pathways, including the TLS, Fanconi's anemia (FA), and homologous repair (HR) pathways (Dronkert and Kanaar, 2001). Although the complete mechanistic details of how these pathways accomplish this repair remain unknown, it is clear that defects in these pathways dramatically sensitize cells to agents that cause interstrand cross-links, including the platinating agents (Dronkert and Kanaar, 2001). It is noteworthy that defects in these pathways are frequently found in tumor cells, raising the possibility that these repair deficiencies contribute to enhanced sensitivity of tumor cells to platinating agents (Gudmundsdottir and Ashworth, 2006; Lyakhovich and Surralles, 2006; Gossage and Madhusudan, 2007; Miyagawa, 2008).

In addition to triggering repair pathways, stalled replication forks also activate the Rad9-Hus1-Rad1 (9-1-1)-ATR-Chk1 signaling pathway (Cimprich and Cortez, 2008). The pathway is initiated when the replicative helicase that unwinds the double-stranded DNA continues advancing in front of the stalled DNA polymerase. This creates extensive re-

This work was supported by the National Institutes of Health National Cancer Institute [Grant CA084321] and the Mayo Foundation.

Article, publication date, and citation information can be found at <http://molpharm.aspetjournals.org>.  
doi:10.1124/mol.109.055178.

[S] The online version of this article (available at <http://molpharm.aspetjournals.org>) contains supplemental material.

**ABBREVIATIONS:** TLS, translesion synthesis; 9-1-1, Rad9-Hus1-Rad1; FA, Fanconi's anemia; HR, homologous recombination; siRNA, small interfering RNA; AZD7762, 3-(carbamoylamino)-5-(3-fluorophenyl)-N-(3-piperidyl)thiophene-2-carboxamide; ES, embryonic stem.

gions of single-stranded DNA that are coated with the replication protein A complex. The replication protein A-coated single-stranded DNA then triggers the Rad17-mediated loading of the 9-1-1 clamp complex and the binding of the ATM and Rad3-related-ATR-interacting protein complex. The chromatin-bound 9-1-1 clamp, which associates with the ATR activator TopBp1, then triggers ATR activation (Burrows and Elledge, 2008). Activated ATR phosphorylates multiple substrates that regulate DNA repair and cell cycle arrest, including Chk1, which helps cells survive replication stress by preventing the firing of origins of replication, delaying G<sub>2</sub> exit, stabilizing the stalled replication forks, and regulating DNA repair (Cimprich and Cortez, 2008).

Consistent with the multiple roles of the 9-1-1-ATR-Chk1 pathway in regulating cell cycle arrest, DNA repair, and replication fork stability, much work has now shown that the pathway plays a pivotal role in helping cells survive a wide range of genotoxic stresses, including radio- and chemotherapies. These findings have provoked intense interest in pharmacologically targeting this pathway as a means to increase the cytotoxicity of genotoxic cancer therapies, with most of these efforts focused on identifying small-molecule inhibitors of Chk1, the most “druggable” component in the signaling pathway. Consistent with that prediction, recent work has shown that Chk1 inhibitors potentiate the activity of nucleoside analogs and topoisomerase I inhibitors in cell lines and xenografts, and these inhibitors are now in early-stage clinical trials in combination with gemcitabine and irinotecan (Ashwell and Zabludoff, 2008).

Although platinating agents are among the most widely used chemotherapy agents, little is known about what checkpoint signaling pathways are activated by these agents or how these pathways affect the survival of tumor cells treated with these agents. To that end, we performed a stepwise analysis and examined the role the 9-1-1-ATR-Chk1 pathway in cells treated with platinating agents to gain insight into which aspects of this signaling pathway are important for tumor cell survival and to assess whether Chk1 plays an important role in facilitating tumor cell survival after treatment with platinating agents.

## Materials and Methods

**Reagents.** Cisplatin and carboplatin were from NovaPlus (Novation, Irving, TX). Oxaliplatin was from Sigma-Aldrich (St. Louis, MO). Gemcitabine was obtained from Eli Lilly & Co. (Indianapolis, IN). Antibodies that recognize the indicated proteins were obtained as follows: Chk1 and ATM, from Santa Cruz Biotechnology (Santa Cruz, CA); Rad18 from Novus Biologicals (Littleton, CO); Rad51 from Thermo Fisher Scientific (Waltham, MA); Cdc25A from Neomarkers (Fremont, CA); phospho-Ser<sup>345</sup>-Chk1 and BRCA1 from Cell Signaling Technology (Danvers, MA); Rad9 from Volkmer and Karnitz (1999); ATR and BRCA2 from Calbiochem (San Diego, CA); FancD2 from GeneTex (Irvine, CA); heat shock protein 90 from David Toft (Mayo Clinic, Rochester, MN); and  $\beta$ -actin from Sigma. The Chk1/Chk2 inhibitor AZD7762 was purchased from Axon Medchem BV (Groningen, The Netherlands).

**Cell Culture, siRNA Transfections, Clonogenic Assays, and Drug Treatment.** HeLa, HCT-116, and U2OS cells were grown in RPMI 1640 medium supplemented with 10% fetal bovine serum. Stable clones of *Rad9*( $-/-$ ) mouse embryonic stem (ES) cells (Hopkins et al., 2004) transfected with empty vector or expressing wild-type *Rad9* were derived and cultured as described previously (Roos-Mattjus et al., 2003). The following siRNAs (synthesized by Thermo Fisher Scientific) were used: luciferase, CUUACGUGAGUACU-

UCGA (Elbashir et al., 2001); ATR, CCUCCGUGAUGUUGCUUGA (Casper et al., 2002); Chk1, GCGUGCCGUGACUGUCCA (Zhao et al., 2002); BRCA1, GUGGGUGUUGGACAGUGUA (Bartz et al., 2006); BRCA2, GACUCUAGGUCAAGAUUUA (Bartz et al., 2006); Rad51, CUCCUAGAGGUGAAACCCU (Lio et al., 2004); ATM, GCACCAGUCCAGUAUUGGC (Wang and Qin, 2003); Rad9, ACUUGAAUCUUAGCAUUA; Rad18, GCUCUCUGAUCGUGAUUUA; and FancD2, GGUCAGAGCUGUAUUAUUC. On day 1, siRNA (900 ng) was combined with 12  $\mu$ l of HiPerFect reagent (Qiagen, Valencia, CA), incubated at room temperature for 5 min, and added to cells in the well for a final siRNA concentration of 30 nM. Transfections were repeated on day 2. On day 3, cells were replated in 100-mm tissue culture dishes. On day 4, cells were trypsinized, used to set up clonogenic assays, and lysed for immunoblotting. Clonogenic assays were performed as described previously (Karnitz et al., 2005) using 24-h drug treatments. Cell lysis and immunoblotting were performed as described previously (Volkmer and Karnitz, 1999), and blots were developed with SuperSignal West Pico chemiluminescent substrate (Pierce, Rockford, IL).

**Cell Cycle Analysis.** Trypsinized cells were permeabilized with ice-cold 70% ethanol in phosphate-buffered saline, stored at  $-20^{\circ}\text{C}$  for 1 h, centrifuged, resuspended in phosphate-buffered saline containing 50  $\mu\text{g/ml}$  propidium iodide and 100  $\mu\text{g/ml}$  RNase, incubated at  $30^{\circ}\text{C}$  for 30 min, and analyzed by flow microfluorometry (FACS-can; BD Biosciences, San Jose, CA).

## Results

**Cells Lacking Rad9 Are Sensitive to the Antiproliferative Effects of Cisplatin.** To begin a stepwise assessment of the role(s) of 9-1-1-ATR-Chk1 pathway in tumor cells treated with cisplatin, initial experiments focused on Rad9, a key participant in DNA repair and Chk1 signaling. Using a previously described model system of mouse *Rad9*( $-/-$ ) ES cells stably transfected to express wild-type Rad9 or transfected with empty vector (Roos-Mattjus et al., 2003; Hopkins et al., 2004), we assessed the impact of Rad9 status on the ability of these cells to form colonies after a 24-h treatment with graded concentrations of cisplatin. As shown in Fig. 1A, cells lacking Rad9 were exceptionally sensitive to the antiproliferative effects of this cross-linking agent.

**Rad9 and ATR Depletion Sensitizes HeLa Cells to Cisplatin.** To further evaluate the role of Rad9 and ATR in resistance to cisplatin (and to demonstrate that the results of a Rad9 deficiency were not specific to mouse ES cells), we analyzed the effects of depleting Rad9 and ATR from HeLa cells using siRNAs (Fig. 1B). Because we had shown previously that Rad9 and ATR play critical roles in helping tumor cells (including HeLa cells) survive treatment with gemcitabine, a nucleoside analog that disrupts DNA replication (Karnitz et al., 2005), we also treated the cells with gemcitabine. Depletion of either Rad9 or ATR sensitized HeLa cells to cisplatin (Fig. 1C) and gemcitabine (Fig. 1D), thus demonstrating that these checkpoint proteins play critical roles in facilitating the survival of cisplatin-treated tumor cells.


**Disrupting Chk1 Signaling Does Not Sensitize HeLa Cells to Platinating Agents.** An important target substrate for activated ATR is Chk1, a protein kinase that participates in blocking cell cycle progression and regulating DNA repair after DNA damage or replication stress (Ashwell and Zabludoff, 2008). Given the central role of Chk1 in ATR signaling and the fact that Chk1 inhibition sensitizes many tumor cell lines to genotoxic chemotherapies, including gemcitabine (Fig. 1D) (Karnitz et al., 2005), we asked whether

Chk1 depletion (Fig. 1B) affected HeLa cell clonogenicity after treatment with cisplatin, oxaliplatin, or carboplatin (Fig. 1, C, E, and F, respectively). It is surprising that even though Chk1 depletion sensitized cells to gemcitabine (Fig. 1D), Chk1 depletion did not sensitize HeLa cells to any of the platinating agents.

To further probe the role of Chk1 in cisplatin cytotoxicity, we used AZD7762, a small molecule that inhibits both Chk1 and Chk2 with similar potency (Zabludoff et al., 2008). Although this agent dramatically sensitized HeLa cells to gemcitabine (Fig. 2A), it did not sensitize the cells to cisplatin (Fig. 2B). This result suggests that neither Chk1 nor Chk2 plays an important role in helping cells survive cisplatin treatment. Consistent with this finding, codepletion of Chk1 and Chk2 with siRNAs (Fig. 2C) did not sensitize HeLa cells to cisplatin (Fig. 2D). Taken together, these results demonstrate that although ATR is important for tumor cell survival after treatment with platinating agents, Chk1 is not, even when Chk2 is also inhibited.

**Cisplatin Activates Chk1.** In view of the unexpected finding that Chk1 depletion did not sensitize HeLa cells to platinating agents, we asked whether the DNA damage induced by cisplatin could activate Chk1. HeLa cells were


treated with cisplatin concentrations that reduced clonogenicity by 10% (250 nM) and 90% (600 nM), and Chk1 phosphorylation on Ser<sup>345</sup>, a site phosphorylated by ATR and required for Chk1 activation (Liu et al., 2000), was assessed (Fig. 3A). In addition, to demonstrate that the phosphorylated Chk1 was relaying signals to downstream targets, we analyzed Cdc25A, a Chk1 substrate that is targeted for proteasomal degradation after Chk1-mediated phosphorylation. Consistent with previous results, cisplatin induced Chk1 phosphorylation under all conditions tested, and there was a corresponding decrease in the levels of Cdc25A (Fig. 3A, lanes 2–5). As a control for this experiment, we initially treated cells with concentrations of gemcitabine that also reduced clonogenicity by 10% (30 nM) and 90% (100 nM), but we observed nearly undetectable Chk1 phosphorylation (Fig. 3A, lanes 6 and 8, and data not shown); notably, however, a high concentration of gemcitabine (1000 nM) induced robust Chk1 phosphorylation and Cdc25A degradation (Fig. 3A, lane 7). Taken together, these results suggest that cisplatin—at isotonic concentrations—is a better inducer of Chk1 phosphorylation than gemcitabine; however, Chk1 only plays a role in helping cells survive gemcitabine but not cisplatin treatment.



**Fig. 1.** Rad9 and ATR but not Chk1 are important for tumor resistance to platinating agents. **A**, *Rad9*<sup>-/-</sup> murine ES cells stably transfected with empty vector or expressing wild-type Rad9 (inset) were exposed to the indicated cisplatin concentrations for 24 h and analyzed for clonogenic survival. **B** to **F**, HeLa cells were transfected with luciferase (Con), ATR, Chk1, or Rad9 siRNAs, and 48 h later, lysates were sequentially immunoblotted (**B**) for ATR, Rad9, Chk1, and β-actin. The remainder of the cells were treated with the indicated concentrations of cisplatin (**C**), gemcitabine (**D**), oxaliplatin (**E**), or carboplatin (**F**) for 24 h and analyzed for clonogenicity.




**Depleting Chk1 Disrupts the Cisplatin-Induced S-Phase Arrest.** A major function of Chk1 after genotoxic stress is to block the origin firing and S-phase progression. To



**Fig. 2.** Chk1 inhibition and Chk2 codepletion do not affect cisplatin cytotoxicity. A and B, HeLa cells were treated with the indicated concentrations of dimethyl sulfoxide (DMSO) or AZD7762 (AZD) simultaneously with the indicated concentrations of gemcitabine or cisplatin for 24 h and analyzed for clonogenicity. C and D, HeLa cells were transfected with luciferase (Luc), Chk1, Chk2, or Chk1 and Chk2 siRNAs and 48 h later were analyzed for Chk1, Chk2, and heat shock protein 90 expression (Hsp90; A) and for clonogenic survival (B) after 24-h treatment with the indicated concentrations of cisplatin.

assess whether the Chk1 activated in cisplatin-treated HeLa cells was indeed promoting an S-phase arrest, we examined the cisplatin-induced cell cycle arrest in control and Chk1-depleted HeLa cells. For these assays, cells were treated for 20 h with 1 and 4  $\mu$ M cisplatin. (These comparatively high concentrations of cisplatin were used because we did not observe robust S-phase accumulation in the control cells at lower concentrations.) Consistent with previously published results, 1  $\mu$ M cisplatin induced mid-S-phase accumulation in control cells, with the higher concentration of cisplatin causing an early S-phase accumulation (Fig. 3B). In contrast, in Chk1-depleted cells, this S-phase arrest was partially disrupted and the cells accumulated in late S phase or G<sub>2</sub>/M. Taken together, these results suggest that Chk1-mediated inhibition of S-phase progression does not play an important role in helping HeLa cells survive cisplatin treatment.

**Multiple Tumor Cell Lines Are Not Sensitized to Cisplatin by Chk1 Depletion.** To further explore the surprising finding that Chk1 depletion does not sensitize HeLa cells to cisplatin, we examined the effect of depleting Chk1 in additional cell lines. HCT-116 and U2OS cells, which were derived from a colorectal carcinoma and an osteosarcoma, respectively, were selected for these studies because patients with these tumors are often treated with platinating agents. Consistent with the results for HeLa cells (Fig. 1), Chk1 depletion did not sensitize either HCT-116 or U2OS cells to cisplatin, whereas both cell lines were sensitized to gemcitabine (Fig. 4, A–D). Likewise, Chk1 depletion did not sensitize HCT-116 cells to oxaliplatin, an agent that is often used to treat colon cancer, or the lung cancer cell line A549 to cisplatin (data not shown). Collectively, these results show that Chk1 does not play a rate-limiting role in preventing the antiproliferative effects of platinating agents in multiple cell



**Fig. 3.** Cisplatin induces activating Chk1 phosphorylation and causes Chk1-dependent S-phase arrest. A, HeLa cells were exposed to vehicle (–) or the indicated concentrations of cisplatin or gemcitabine for 4 or 24 h. Cell lysates were then sequentially immunoblotted for phospho-Ser<sup>345</sup>-Chk1 (P-Chk1), total Chk1, and Cdc25A. \*, nonspecific band. B, HeLa cells transfected with luciferase (Control) or Chk1 siRNAs were treated with indicated concentrations of cisplatin for 24 h, stained with propidium iodide, and analyzed by flow microfluorometry.

types, including cell lines derived from tumors that are routinely treated with these drugs.

**Disabling DNA Repair Pathways Does Not Make Cisplatin-Treated Tumor Cells Reliant on Chk1.** We reasoned that Chk1 signaling pathways might assume increased importance if the pathways that repair platinum-induced lesions were disabled. Many of the tumors that are treated with cisplatin harbor defects in repair pathways for cisplatin-induced lesions. Thus, if Chk1 depletion sensitized a tumor cell with a defect in a specific repair pathway, then Chk1 inhibitors might be useful to sensitize these tumors to platinating agents. To test this idea, we first depleted HeLa cells of Rad51, BRCA1, Rad18, FancD2, or BRCA2 (Supplemental Fig. 1), all of which participate in the repair of cisplatin-induced lesions. In all cases, knockdown of any single repair protein increased the sensitivity of the cells to cisplatin (Fig. 5, A–E). When the effects of simultaneously depleting Chk1 with each individual repair protein were examined, we observed that in no case did codepletion of Chk1 and the repair protein further sensitize the cells to cisplatin. To the contrary, simultaneous depletion of Rad18 or FancD2 with Chk1 rendered cells less sensitive to cisplatin than depletion of Rad18 or FancD2 alone (Fig. 5, A and E).


## Discussion

In the present study, we examined the role of the 9-1-1-ATR-Chk1 pathway in protecting a series of tumor cell lines from the antiproliferative effects of cisplatin and other platinating agents. Previously published studies, using small-molecule Chk1 inhibitors and RNA interference approaches, demonstrated variable sensitization of some tumor cell lines to platinating agents when Chk1 is disabled (Gao et al., 2006; Blasina et al., 2008; Ganzinelli et al., 2008). However, none of these studies addressed the role of the entire 9-1-1-ATR-Chk1 pathway, nor did they examine the effects of disabling specific DNA repair pathways in the context of Chk1 inhibition. Our studies demonstrate that cells lacking Rad9 and ATR are exquisitely

sensitive to platinating agents. In stark contrast, however, Chk1 depletion did not enhance the antiproliferative effects of cisplatin in multiple cell lines, even though Chk1 was activated and relayed a checkpoint signal that caused Cdc25A degradation and slowed S-phase progression in cisplatin-treated cells. In addition, we showed that depleting key repair proteins, which are part of DNA repair pathways that are frequently disabled in a variety of tumor cells, did not render cells more dependent on Chk1. In fact, in some cases, depleting Chk1 from cells lacking specific repair proteins reversed the sensitivity caused by the deficiency of the repair protein.

Multiple studies have shown that Chk1 depletion and Chk1 inhibitors potently sensitize tumor cells to the damage induced by S-phase-active agents such as gemcitabine, hydroxyurea, or 5-fluorouracil (Cho et al., 2005; Karnitz et al., 2005; Morgan et al., 2006; Robinson et al., 2006; Matthews et al., 2007; Blasina et al., 2008). During S-phase, Chk1 contributes to cell survival by blocking the firing of unfired origins of replication, preventing cells from exiting G<sub>2</sub>, stabilizing stalled replication forks, and regulating DNA repair (Enders, 2008). Because the intrastrand and interstrand cross-links caused by cisplatin are also potent inhibitors of DNA replication, we expected that Chk1 would also facilitate tumor cell survival after cisplatin treatment. Surprisingly, however, even though cisplatin provoked robust Chk1 activation and this activation was important in blocking progression through S-phase, Chk1 depletion did not sensitize these tumor cell lines to platinating agents.

Such results strongly suggest that not all stalled replication forks require Chk1 to maintain their stability. Moreover, they also indicate that the Chk1-mediated block of origin firing does not contribute to increased cell survival. One possible explanation is that the Chk1-mediated suppression of origin firing is most important when continued replication would actually create additional DNA damage, such as when additional gemcitabine is incorporated into the genome. In contrast, when the damage is pre-existing, as with cisplatin,



**Fig. 4.** Chk1 depletion does not sensitize HCT-116 and U2OS cells to cisplatin. A to D, HCT-116 cells (A and B) or U2OS (C and D) transfected with luciferase (Control), ATR, or Chk1 siRNAs were treated with the indicated concentrations of cisplatin or gemcitabine for 24 h, and clonogenic assays were performed.


additional origin firing would not incorporate further damage into the genome. This latter point is of particular interest because a recent study has shown that the repair of inter-strand cross-links is initiated only when two opposing replication forks converge on the lesion (Räschle et al., 2008), thus raising the possibility that the repair of these lesions might depend on the activation of additional replication origins.

Chk1, in addition to regulating origin firing and replication of fork stability, also positively regulates DNA repair pathways that are important for the repair of interstrand cross-links in at least two ways. First, Chk1 promotes HR, in part by phosphorylating Rad51 (Sørensen et al., 2005; Huang et al., 2008). Second, Chk1 phosphorylates FancE (Wang et al., 2007), which stimulates the repair of inter-strand cross-links through the FA pathway (Wang, 2007). Because our results clearly demonstrate that the HR and FA pathways are important in HeLa cells treated with cisplatin, the lack of an effect on cell survival when Chk1 is depleted suggests that Chk1 does not play a major regulatory role in these repair pathways in the cell lines examined.

We also explored the possibility that Chk1 might only become important in cisplatin-treated cells when specific DNA repair pathways were disrupted. This is of particular relevance because tumors often have defective DNA repair pathways, and the defects in these pathways probably contribute to the sensitivity of the tumor to chemotherapy regimens (García and Benitez, 2008; Powell and Kachnic, 2008).

For example, patients with defects in *BRCA1* and *BRCA2* have better overall responses (including longer survival) to platinum-based therapies (Foulkes, 2006; Sakai et al., 2008), probably because *BRCA1* and *BRCA2* play critical roles in repairing the cisplatin-induced damage. If Chk1 was important in such cells, then tumors that harbor these defects might be good candidates for clinical trials that combine cisplatin and a Chk1 inhibitor. We did not observe such an outcome. Instead, we found that Chk1 depletion actually reduced the sensitivity of cells with disabled FA (i.e., FancD2) and TLS (i.e., Rad18) pathways. Not only do these results further suggest that Chk1 inhibitors might not be useful agents to sensitize tumors to platinating agents, they also suggest that the addition of a Chk1 inhibitor to combination therapies containing cisplatin should be undertaken with great caution.

The present findings suggest that Chk1 inhibitors may be of limited use to sensitize tumor cells to platinum-induced damage. In fact, given that Chk1 depletion actually reversed the sensitivity of cells with defects in repair pathways that are often defective in tumors treated with cisplatin, the use of such inhibitors may be counterproductive in some patients. In contrast, because both Rad9 and ATR depletion cause profound sensitization to cisplatin, the identification of small-molecule inhibitors that disrupt this portion of the pathway may be effective agents to sensitize tumors to platinating agents.



**Fig. 5.** Chk1 depletion does not further sensitize cells with defects in pathways that repair cisplatin-induced DNA lesions. A to E, HeLa cells transfected with siRNAs to FancD2 (A), Rad51 (B), BRCA1 (C), BRCA2 (D), or Rad18 (E), alone or in combination with Chk1 siRNA, were treated for 24 h with the indicated concentrations of cisplatin and analyzed for clonogenicity.



## References

- Ashwell S and Zabludoff S (2008) DNA damage detection and repair pathways—recent advances with inhibitors of checkpoint kinases in cancer therapy. *Clin Cancer Res* **14**:4032–4037.
- Bartz SR, Zhang Z, Burchard J, Imakura M, Martin M, Palmieri A, Needham R, Guo J, Gordon M, Chung N, et al. (2006) Small interfering RNA screens reveal enhanced cisplatin cytotoxicity in tumor cells having both BRCA network and TP53 disruptions. *Mol Cell Biol* **26**:9377–9386.
- Blasina A, Hallin J, Chen E, Arango ME, Kravynov E, Register J, Grant S, Ninkovic S, Chen P, Nichols T, et al. (2008) Breaching the DNA damage checkpoint via PF-00477736, a novel small-molecule inhibitor of checkpoint kinase 1. *Mol Cancer Ther* **7**:2394–2404.
- Burrows AE and Elledge SJ (2008) How ATR turns on: TopBP1 goes on ATRIP with ATR. *Genes Dev* **22**:1416–1421.
- Casper AM, Nghiem P, Arlt MF, and Glover TW (2002) ATR regulates fragile site stability. *Cell* **111**:779–789.
- Cho SH, Toouli CD, Fujii GH, Crain C, and Parry D (2005) Chk1 is essential for tumor cell viability following activation of the replication checkpoint. *Cell Cycle* **4**:131–139.
- Cimprich KA and Cortez D (2008) ATR: an essential regulator of genome integrity. *Nat Rev Mol Cell Biol* **9**:616–627.
- Donaldson KL, Goolsby GL, and Wahl AF (1994) Cytotoxicity of the anticancer agents cisplatin and Taxol during cell proliferation and the cell cycle. *Int J Cancer* **57**:847–855.
- Dronkert ML and Kanaar R (2001) Repair of DNA interstrand cross-links. *Mutat Res* **486**:217–247.
- Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, and Tuschl T (2001) Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. *Nature* **411**:494–498.
- Enders GH (2008) Expanded roles for Chk1 in genome maintenance. *J Biol Chem* **283**:17749–17752.
- Foulkes WD (2006) BRCA1 and BRCA2: chemosensitivity, treatment outcomes and prognosis. *Fam Cancer* **5**:135–142.
- Ganzinelli M, Carrassa L, Crippa F, Tavecchio M, Broggin M, and Damia G (2008) Checkpoint kinase 1 down-regulation by an inducible small interfering RNA expression system sensitized in vivo tumors to treatment with 5-fluorouracil. *Clin Cancer Res* **14**:5131–5141.
- Gao Q, Huang X, Tang D, Cao Y, Chen G, Lu Y, Zhuang L, Wang S, Xu G, Zhou J, et al. (2006) Influence of chk1 and plk1 silencing on radiation- or cisplatin-induced cytotoxicity in human malignant cells. *Apoptosis* **11**:1789–1800.
- García MJ and Benítez J (2008) The Fanconi anaemia/BRCA pathway and cancer susceptibility. Searching for new therapeutic targets. *Clin Transl Oncol* **10**:78–84.
- Gossage L and Madhusudan S (2007) Current status of excision repair cross complementing-group 1 (ERCC1) in cancer. *Cancer Treat Rev* **33**:565–577.
- Gudmundsdottir K and Ashworth A (2006) The roles of BRCA1 and BRCA2 and associated proteins in the maintenance of genomic stability. *Oncogene* **25**:5864–5874.
- Hopkins KM, Auerbach W, Wang XY, Hande MP, Hang H, Wolgemuth DJ, Joyner AL, and Lieberman HB (2004) Deletion of mouse rad9 causes abnormal cellular responses to DNA damage, genomic instability, and embryonic lethality. *Mol Cell Biol* **24**:7235–7248.
- Huang M, Miao ZH, Zhu H, Cai YJ, Lu W, and Ding J (2008) Chk1 and Chk2 are differentially involved in homologous recombination repair and cell cycle arrest in response to DNA double-strand breaks induced by camptothecins. *Mol Cancer Ther* **7**:1440–1449.
- Karnitz LM, Flatten KS, Wagner JM, Loegering D, Hackbarth JS, Arlander SJ, Vroman BT, Thomas MB, Baek YU, Hopkins KM, et al. (2005) Gemcitabine-induced activation of checkpoint signaling pathways that affect tumor cell survival. *Mol Pharmacol* **68**:1636–1644.
- Kelland L (2007) The resurgence of platinum-based cancer chemotherapy. *Nat Rev Cancer* **7**:573–584.
- Lehmann AR (2006) Translesion synthesis in mammalian cells. *Exp Cell Res* **312**:2673–2676.
- Lio YC, Schild D, Brenneman MA, Redpath JL, and Chen DJ (2004) Human Rad51C deficiency destabilizes XRCC3, impairs recombination, and radiosensitizes S/G2-phase cells. *J Biol Chem* **279**:42313–42320.
- Liu Q, Guntuku S, Cui XS, Matsuoka S, Cortez D, Tamai K, Luo G, Carattini-Rivera S, DeMayo F, Bradley A, et al. (2000) Chk1 is an essential kinase that is regulated by ATR and required for the G<sub>2</sub>/M DNA damage checkpoint. *Genes Dev* **14**:1448–1459.
- Lyakhovich A and Surralles J (2006) Disruption of the Fanconi anemia/BRCA pathway in sporadic cancer. *Cancer Lett* **232**:99–106.
- Matthews DJ, Yakes FM, Chen J, Tadano M, Bornheim L, Clary DO, Tai A, Wagner JM, Miller N, Kim YD, et al. (2007) Pharmacological abrogation of S-phase checkpoint enhances the anti-tumor activity of gemcitabine in vivo. *Cell Cycle* **6**:104–110.
- Miyagawa K (2008) Clinical relevance of the homologous recombination machinery in cancer therapy. *Cancer Sci* **99**:187–194.
- Morgan MA, Parsels LA, Parsels JD, Lawrence TS, and Maybaum J (2006) The relationship of premature mitosis to cytotoxicity in response to checkpoint abrogation and antimetabolite treatment. *Cell Cycle* **5**:1983–1988.
- Powell SN and Kachnic LA (2008) Therapeutic exploitation of tumor cell defects in homologous recombination. *Anticancer Agents Med Chem* **8**:448–460.
- Räschle M, Knipsheer P, Enoiu M, Angelov T, Sun J, Griffith JD, Ellenberger TE, Schärer OD, and Walter JC (2008) Mechanism of replication-coupled DNA inter-strand crosslink repair. *Cell* **134**:969–980.
- Robinson HM, Jones R, Walker M, Zachos G, Brown R, Cassidy J, and Gillespie DA (2006) Chk1-dependent slowing of S-phase progression protects DT40 B-lymphoma cells against killing by the nucleoside analogue 5-fluorouracil. *Oncogene* **25**:5359–5369.
- Roos-Mattjus P, Hopkins KM, Oestreich AJ, Vroman BT, Johnson KL, Naylor S, Lieberman HB, and Karnitz LM (2003) Phosphorylation of human Rad9 is required for genotoxin-activated checkpoint signaling. *J Biol Chem* **278**:24428–24437.
- Sakai W, Swisher EM, Karlan BY, Agarwal MK, Higgins J, Friedman C, Villegas E, Jacquemont C, Farrugia DJ, Couch FJ, et al. (2008) Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. *Nature* **451**:1116–1120.
- Sørensen CS, Hansen LT, Dziegielewska J, Syljuåsen RG, Lundin C, Bartek J, and Helleday T (2005) The cell-cycle checkpoint kinase Chk1 is required for mammalian homologous recombination repair. *Nat Cell Biol* **7**:195–201.
- Volkmer E and Karnitz LM (1999) Human homologs of *Schizosaccharomyces pombe* Rad1, Hus1, and Rad9 form a DNA damage-responsive protein complex. *J Biol Chem* **274**:567–570.
- Wang W (2007) Emergence of a DNA-damage response network consisting of Fanconi anaemia and BRCA proteins. *Nat Rev Genet* **8**:735–748.
- Wang X, Kennedy RD, Ray K, Stuckert P, Ellenberger T, and D'Andrea AD (2007) Chk1-mediated phosphorylation of FANCE is required for the Fanconi anemia/BRCA pathway. *Mol Cell Biol* **27**:3098–3108.
- Wang Y and Qin J (2003) MSH2 and ATR form a signaling module and regulate two branches of the damage response to DNA methylation. *Proc Natl Acad Sci U S A* **100**:15387–15392.
- Zabludoff SD, Deng C, Grondine MR, Sheehy AM, Ashwell S, Caleb BL, Green S, Haye HR, Horn CL, Janetka JW, et al. (2008) AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies. *Mol Cancer Ther* **7**:2955–2966.
- Zhao H, Watkins JL, and Piwnicka-Worms H (2002) Disruption of the checkpoint kinase 1/cell division cycle 25A pathway abrogates ionizing radiation-induced S and G<sub>2</sub> checkpoints. *Proc Natl Acad Sci U S A* **99**:14795–14800.

---

**Address correspondence to:** Dr. Larry M. Karnitz, Division of Oncology Research, Mayo Clinic, 200 First Street SW, Gonda 19-300, Rochester, MN 55905. E-mail: karnitz.larry@mayo.edu

---